Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CERE-110: Adeno-Associated Virus injection Surgery
CERE-110: Adeno-Associated Virus Surgery · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CERE-110 | EXPERIMENTAL | CERE-110: Adeno-Associated Virus Delivery of NGF |
| Placebo | SHAM_COMPARATOR | Placebo Surgery |
| Name | Type | Description |
|---|---|---|
| CERE-110: Adeno-Associated Virus injection Surgery | DRUG | Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure. |
| Placebo Surgery | PROCEDURE | Placebo Surgery |
Inclusion Criteria: * Diagnosis of mild to moderate Alzheimer's disease * Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months * A study partner who can attend all study visits * Good general health * Medically able to undergo neurosurgery Exclusion Cr...
Top 20 of 23 competitors
CERE-110 is an investigational gene therapy that was studied for the treatment of mild to moderate Alzheimer's disease. It was delivered by stereotactic injection into the brain during a surgical procedure. The program is in Phase 2 development and is not approved for any indication.
CERE-110 is being developed by Sangamo Therapeutics, Inc., which trades on the Nasdaq under the ticker SGMO. Sangamo is the sponsor of the clinical program for this gene therapy candidate in Alzheimer's disease.
CERE-110 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program remains investigational and has not been approved by the FDA for Alzheimer's disease or any other indication.
CERE-110 was evaluated in one completed Phase 2 trial, NCT00876863, titled a randomized, controlled study of CERE-110 in subjects with mild to moderate Alzheimer's disease. The trial enrolled 49 participants in the United States, was randomized, double blind, and sham controlled, and included participants aged 55 years and older.
Yes. CERE-110 is also referred to as CERE-110: Adeno-Associated Virus injection Surgery. Both names describe the same gene therapy candidate developed by Sangamo Therapeutics for Alzheimer's disease, which is administered through an adeno-associated virus based surgical injection into the brain.